You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

mass. mover

Biogen Idec slips after stock’s rating is cut

Weston-based Biogen Idec makes  drugs to treat neurodegenerative diseases, hemophilia, and autoimmune disorders.

Suzanne Kreiter/Globe Staff

Weston-based Biogen Idec makes drugs to treat neurodegenerative diseases, hemophilia, and autoimmune disorders.

Continue reading below

Biogen Idec Inc., maker of the multiple sclerosis drug Tecfidera, fell after Citigroup cut the stock to “neutral” from “buy.” The shares had rallied 52 percent this year through Tuesday, Bloomberg News reported. Citi’s analyst cited concerns about regulatory protections for Tecfidera in the European Union when other drug makers submit applications to make generic versions.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week